Elias Badal Rashu

Medicine & Life Sciences

1. Amino Acids 10%
2. Base Pairing 6%
3. Biopsy 17%
4. C-Peptide 17%
5. Child 7%
6. Cholesterol Ester Storage Disease 72%
7. Cohort Studies 33%
8. Dipeptidyl-Peptidase IV Inhibitors 10%
9. Disease Progression 5%
10. Dyslipidemias 6%
11. Enzyme Replacement Therapy 8%
12. Exons 5%
13. Fasting 9%
14. Fatty Liver 50%
15. fibroblast growth factor 21 16%
16. Fibrosis 52%
17. Gastrointestinal Diseases 7%
18. Glucagon 64%
19. Glucagon-Like Peptide 1 14%
20. Glucose 34%
21. Glucose Intolerance 6%
22. Heart Failure 8%
23. Hydroxymethylglutaryl-CoA Reductase Inhibitors 6%
24. Hyperinsulinism 6%
25. Inborn Genetic Diseases 6%
26. Insulin 6%
27. LCZ 696 65%
28. Liver 35%
29. Liver Cirrhosis 33%
30. Liver Diseases 51%
31. Liver Transplantation 24%
32. Logistic Models 5%
33. Meals 19%
34. Neprilysin 52%
35. Non-alcoholic Fatty Liver Disease 100%
36. Pancreatic Hormones 12%
37. Physiological Feedback 5%
38. Prospective Studies 28%
39. Rare Diseases 6%
40. Reference Values 5%
41. Referral and Consultation 29%
42. Regression Analysis 5%
43. Siblings 12%
44. Single Nucleotide Polymorphism 5%
45. Sitagliptin Phosphate 17%
46. Sterol Esterase 9%
47. Type 2 Diabetes Mellitus 42%
48. Ultrasonography 31%
49. Valsartan 5%
50. Veins 14%